Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NWX0RXhKS3m2b4TvfIlkKEG|c3H5 NUnLZZBlPDhiaB?= MmriSG1UVw>? NWXvUotQS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IHPv[ZhxemW|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAxNjZ{IN88US=> NEXvU5czOTV5MkW4PS=>
BAF3 M1fVOWN6fG:2b4jpZ{BCe3OjeR?= MXe0PEBp MlnkSG1UVw>? NHfqZmtEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGwyOTl4TTDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFIvOiEQvF2= M320b|IyPTd{NUi5
BAF3 MkXCR5l1d3SxeHnjJGF{e2G7 MWS0PEBp MXvEUXNQ NWO0c2JSS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIIfpeIghUUN3MDDv[kAxNjJ6IN88US=> MXuyNVU4OjV6OR?=
Kelly NHXqOHJEgXSxdH;4bYMhSXO|YYm= M13ZeGROW09? MoDRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4VtdHliY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCC5aYToJGlEPTBib3[gNE41OiEQvF2= NFrzTG8zOTV5MkW4PS=>
SH-SY5Y M4TCOmN6fG:2b4jpZ{BCe3OjeR?= NXrmTHE5TE2VTx?= MkLrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjV|IN88US=> MXqyNVU4OjV6OR?=
SMS-KCN MlvLR5l1d3SxeHnjJGF{e2G7 MlLHSG1UVw>? M2nKeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0> M1\PZlIyPTd{NUi5
BAF3 NXrJ[5JvS3m2b4TvfIlkKEG|c3H5 NVTKNYVHPDhiaB?= MkDzSG1UVw>? MmPWR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP NGjGNoMzOTV5MkW4PS=>
3T3 MVjGeY5kfGmxbjDBd5NigQ>? MUSxJIg> M1XDOGROW09? NF3UWmpKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? MoLiNlE5OTJ2MUS=
3T3-E MlLJSpVv[3Srb36gRZN{[Xl? M2DEcFEhcA>? MljOSG1UVw>? M{nqU2lvcGmkaYTpc44hd2ZiVFnFNkBie3Onc4Pl[EBoem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC52NEig{txO NYfMOnFiOjF6MUK0NVQ>
A549 M1G2bWtqdmG|ZTDBd5NigQ>? NYPmUW5bOSCq M4HrUmROW09? Mn62TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN M2jjTlIyQDF{NEG0
BAF3-BCL M4jK[GZ2dmO2aX;uJGF{e2G7 M1zDcFEhcA>? NXG4e3hbTE2VTx?= M4\zUmlvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? M1Tmc|IyQDF{NEG0
HEK293 MVHGeY5kfGmxbjDBd5NigQ>? NHTifG4yKGh? M4TyXmROW09? MkHzTY5pcWKrdHnvckBw\iCDWFygZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMkm0JO69VQ>? NH7ie4YzOThzMkSxOC=>
HEK293 MmrHSpVv[3Srb36gRZN{[Xl? NYnmSZJ[OSCq MVXEUXNQ M4jBTmlvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? NEPaRXMzOThzMkSxOC=>
Jurkat Mm\hSpVv[3Srb36gRZN{[Xl? MmDoNUBp MWXEUXNQ M1HOVmlvcGmkaYTpc44hd2ZiTFPLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lke0NUDPxE1? MkHoNlE5OTJ2MUS=
KARPAS299 MV\LbY5ie2ViQYPzZZk> MkLtNUBp NH\K[lJFVVOR MmT5TY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NVfFOIFVOjF6MUK0NVQ>
PAE NXf6[HVtTnWwY4Tpc44hSXO|YYm= M4\Fb|EhcA>? NIXpfFlFVVOR NIHST2RKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= NH7P[VczOThzMkSxOC=>
BAF3 M{L3d2Z2dmO2aX;uJGF{e2G7 MWGyMVMh\A>? MXHEUXNQ MX7Jcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU43PDNizszN MnXVNlM4PDJ{NUK=
KARPAS299 NVrmV4RPS3m2b4TvfIlkKEG|c3H5 NXr0PGZrOi1|IHS= NH7FU2xFVVOR M{PvXmlEPTB;MD6wOlQzKM7:TR?= M3SzdFI{PzR{MkWy
EBC1 NWK3dIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTid414PzJiaB?= MoPlSG1UVw>? MmHHTWM2OD1yLkCyN{DPxE1? NID2fmszOzl7M{OyPC=>
HCT116 M4q4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NkBp MlzkSG1UVw>? NUThVZEzUUN3ME2xOE45OiEQvF2= MVWyN|k6OzN{OB?=
MCF7 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\qSZc4OiCq MkP3SG1UVw>? M2DMcmlEPTB;OT61PEDPxE1? M4rHSVI{QTl|M{K4
MDA-MB-231 M4PqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe0e2k4OiCq Ml\XSG1UVw>? M2\Ld2lEPTB;MUCuPEDPxE1? MknDNlM6QTN|Mki=
MKN45 NWe3[4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2wbnI4OiCq NFTnZ5dFVVOR NWTEWGlFUUN3ME2wMlAyOyEQvF2= M4nMUFI{QTl|M{K4
NCI-H441 NI\5SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX1O|IhcA>? M4LqcmROW09? MkK3TWM2OD1zNz6yOUDPxE1? MkjhNlM6QTN|Mki=
NCI-H661 M12wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjGO|IhcA>? NXPGVoo1TE2VTx?= MmS1TWM2OD1zMT60O{DPxE1? MkTCNlM6QTN|Mki=
SK-MEL-28 NHnJc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGezOJk4OiCq NVLnNWdQTE2VTx?= Mn;NTWM2OD1zMD65O{DPxE1? MmnXNlM6QTN|Mki=
SKOV3 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X4TVczKGh? NHLxXnNFVVOR Mn[4TWM2OD1zMj64OUDPxE1? M1K4SlI{QTl|M{K4
SNU5 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfzWnc5PzJiaB?= NVnicI1VTE2VTx?= NHvMcWJKSzVyPUCuNFE3KM7:TR?= MlXjNlM6QTN|Mki=
NCI-H2228 NWnLUnhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LXZ|czKGh? M1HLUWROW09? NXf0bYRnUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? M3O0SFI1PDN{OUC5
NCI-H3122 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[3NkBp M3n2N2ROW09? NYXWXlhvUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUC4JO69VQ>? M1TkTlI1PDN{OUC5
NCI-H3122 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO1RYtiPzJiaB?= NHzJTGJFVVOR MVHJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KHerdHigTWM2OCCxZjCwMlYzOyEQvF2= NYHPN2I2OjR2M{K5NFk>
NCI-H3122 NVXBUWNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\ubVczKGh? MornSG1UVw>? MXTJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= M4DiblI1PDN{OUC5
NIH-3T3 NV\D[od2U2mwYYPlJGF{e2G7 MYOxJIg> Mn71SG1UVw>? NIDUbIdKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= NEToXGMzPDR|MkmwPS=>
NIH-3T3 NXr4R2dyU2mwYYPlJGF{e2G7 MXyxJIg> MoXiSG1UVw>? MknLTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54MEWg{txO NYfkbGtrOjR2M{K5NFk>
NIH-3T3 NIfFe|hMcW6jc3WgRZN{[Xl? M2flfVEhcA>? NYS5Z4VNTE2VTx?= NYf6WXA4UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP MXSyOFQ{OjlyOR?=
NIH-3T3 NELHUHVMcW6jc3WgRZN{[Xl? MWmxJIg> Mni1SG1UVw>? NUi3SHNNUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD64OFMh|ryP NVfrSYJWOjR2M{K5NFk>
NIH-3T3 MVjLbY5ie2ViQYPzZZk> M3j3eVEhcA>? NXzOe5dmTE2VTx?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> M3vPclI1PDN{OUC5
BAF3 NF3kWWJHfW6ldHnvckBCe3OjeR?= NV;4dldIPzJiaB?= NYLVVmRSTE2VTx?= NUTwS4dkUW6qaXLpeIlwdiCxZjDOVG0wSUyNIITyZY5{\mWldHXkJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEWxJO69VQ>? MVKyOFQ3QDZ|Mh?=
BAF3 M3j6SGN6fG:2b4jpZ{BCe3OjeR?= M2PXVVczKGh? M1XnUmROW09? M{P4OmlEPTB;MD65PEDPxE1? Mk\ONlQ1Pjh4M{K=
NIH-3T3 M{naUWtqdmG|ZTDBd5NigQ>? M2HB[lEhcA>? MkDqTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC5zNkWg{txO MkXRNlQ5OTlzMU[=
NIH-3T3 NWK2WHY6U2mwYYPlJGF{e2G7 NUPZXnZLOSCq M{C5S2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugR|EyPT[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNEe4JO69VQ>? MYOyOFgyQTFzNh?=
NIH-3T3 MYfLbY5ie2ViQYPzZZk> MnPqNUBp M4fWSGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzODKUIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDFwMUS4JO69VQ>? NVTi[4t2OjR6MUmxNVY>
NIH-3T3 M3G4VGtqdmG|ZTDBd5NigQ>? MUexJIg> NHPPVmZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywhf2m2aDDJR|UxKG:oIEOuNFM6KM7:TR?= NVP0bGF1OjR6MUmxNVY>
KARPAS299 NGfwdJNMcW6jc3WgRZN{[Xl? MX65NEBucW5? MVPEUXNQ NGPUXpBKdmirYnn0bY9vKG:oIF7QUU1nfXOnZDDBUGsheGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6xNUDPxE1? MVGyOFkxODd3MB?=
MKN 45 MV;LbY5ie2ViQYPzZZk> NXTxfGhFOSCq M1;DTmROW09? NW\RN3Z7UW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NHTWfngzPDlyMEe1NC=>
A549 MmTXR5l1d3SxeHnjJGF{e2G7 MoHYOFghcA>? NFq5WXZFVVOR M2XiXmlEPTBib3[gOE4xQDRizszN NV7hWGFlOjR7MEC4N|A>
NCI-H1975 NUfYcoNYS3m2b4TvfIlkKEG|c3H5 MXW0PEBp MkfuSG1UVw>? NEDEZolKSzVyIH;mJFcvPTVzIN88US=> Ml30NlQ6ODB6M{C=
NCI-H1993 NGjYN4VEgXSxdH;4bYMhSXO|YYm= MXG0PEBp NFK4O21FVVOR MnH3TWM2OCCxZjCwMlA3OSEQvF2= NHTsdlkzPDlyMEizNC=>
NCI-H1993 NUiyenAySXCxdH;zbZMhSXO|YYm= MXKxJO69VQ>? MYCyOEBp MoGxSG1UVw>? NEXGeFRld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz NWLXW|l4OjR7MEC4N|A>
NIH-3T3 NWe5PY1MS3m2b4TvfIlkKEG|c3H5 MmDXOFghcA>? NXzKcGV4TE2VTx?= NWPjb4pKUUN3MDDv[kAxNjN4NDFOwG0> M{X5U|I1QTByOEOw
EBC1 NYfv[ZhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe3NkBp NEe3TY9FVVOR M3f5O2lEPTBib3[gNE4xODZ7IN88US=> Mlu3NlQ6ODB6M{G=
KARPAS299 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jTcVczKGh? NV7YXlBPTE2VTx?= MWHJR|UxKG:oIECuNkDPxE1? MWGyOFkxODh|MR?=
NB1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HSTWlEPTB;OUGuPVghdk1? MnHEV2FPT0WU
NCI-SNU-5 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFyNT63OUBvVQ>? NIXZ[lRUSU6JRWK=
SR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF{Nj6zNUBvVQ>? NXHhVWg4W0GQR1XS
SF539 M17XVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jCb2lEPTB;MkC0MlI1KG6P M2DLVnNCVkeHUh?=
SU-DHL-1 NFHBdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\ycHFPUUN3ME2zN|YvQDJibl2= MXTTRW5ITVJ?
SCC-3 NVnUWlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLIZnI2UUN3ME2zOVYvPzZibl2= M2rLS3NCVkeHUh?=
DEL Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPMTWM2OD1|NkmuPUBvVQ>? M1fZT3NCVkeHUh?=
CTV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\wSGlEPTB;NUm2MlQ5KG6P MkfnV2FPT0WU
EM-2 M{\0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13kRmlEPTB;NkCxMlM1KG6P M4rVV3NCVkeHUh?=
MHH-CALL-2 NH;q[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfLTWM2OD14OEKuOVchdk1? NVH3OFlsW0GQR1XS
KM12 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PSbWlEPTB;N{C2Mlkhdk1? M{HYeXNCVkeHUh?=
KINGS-1 NVTGXW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTd2OT63OUBvVQ>? MXjTRW5ITVJ?
MEG-01 NFOwW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFixVnhKSzVyPUi1O{43PiCwTR?= M{LL[XNCVkeHUh?=
BV-173 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LON2lEPTB;MT6wOVk6PyEQvF2= M1G4PHNCVkeHUh?=
LAMA-84 NELKcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrCTWM2OD1zLkO4NlgzKM7:TR?= NHjj[JRUSU6JRWK=
KARPAS-299 NYLVWolZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvrTIdKSzVyPUGuOFA5PjFizszN MV\TRW5ITVJ?
K-562 NIf5fHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33he2lEPTB;MT63NlI3QSEQvF2= MYLTRW5ITVJ?
SK-LMS-1 M3roZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHrTWM2OD1zLke2PFY4KM7:TR?= Mk\SV2FPT0WU
MOLT-16 M{nWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXNUGxUUUN3ME2xMlk2PTd3IN88US=> NX\XZnVuW0GQR1XS
CMK MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rzdWlEPTB;MT65OlE2QSEQvF2= NFn0fphUSU6JRWK=
ST486 NIXne|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG5N3V1UUN3ME2yMlQ{ODd|IN88US=> NGXINXpUSU6JRWK=
CI-1 NHrCZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO0U25KSzVyPUKuOFk3PTlizszN NFz0dolUSU6JRWK=
KP-N-RT-BM-1 NEPyOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjucldKSzVyPUKuO|AyOjJizszN M1XR[nNCVkeHUh?=
ALL-PO NGf5cHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfjTWM2OD1|LkG4NlA4KM7:TR?= NFe4NXdUSU6JRWK=
KS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwMkGyNlUh|ryP MXfTRW5ITVJ?
Becker M3nPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[wPIJQUUN3ME20MlI{QTNizszN NGDs[mRUSU6JRWK=
GDM-1 NUPteXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknVTWM2OD12LkK0OlE4KM7:TR?= NEXMT2RUSU6JRWK=
BC-1 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:0TWM2OD12LkS5Nlc4KM7:TR?= M1vHOnNCVkeHUh?=
NB14 M4\3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fuV2lEPTB;ND64N|UzPCEQvF2= NGi5dZBUSU6JRWK=
NOS-1 M4nTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTVwM{O4O|Qh|ryP MX;TRW5ITVJ?
MZ1-PC NID6cXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\6TWM2OD13LkiyNVUyKM7:TR?= MmjFV2FPT0WU
A498 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TGUGlEPTB;Nj6wPFQ4OyEQvF2= MYHTRW5ITVJ?
EW-16 NWX5[IFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTFTWM2OD14LkO3O|c{KM7:TR?= MYPTRW5ITVJ?
NALM-6 NU\EdGtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TGTWlEPTB;Nj62PFM5PyEQvF2= MY\TRW5ITVJ?
EB-3 NF\SW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTdwMEeyN|Mh|ryP NGOxOFdUSU6JRWK=
697 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTlwMkSzNlkh|ryP MnLzV2FPT0WU
Ramos-2G6-4C10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fFc2lEPTB;OT61PVg1OiEQvF2= MonoV2FPT0WU
KNS-81-FD MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTlwNkm2OVMh|ryP M4LRTXNCVkeHUh?=
HUTU-80 NGWxWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rzRWlEPTB;OT63OFY1OiEQvF2= NHG4WnVUSU6JRWK=
LS-411N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfVTWM2OD1zMD6wOVY4KM7:TR?= MkG5V2FPT0WU
RPMI-8402 NXWxUXM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTHNZNjUUN3ME2xNE4yOTZizszN MmXoV2FPT0WU
KU812 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFyLkK5PVEh|ryP NGr5WpBUSU6JRWK=
EW-1 M{TyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrRW5pKSzVyPUGwMlQ1OjVizszN NFHMO2tUSU6JRWK=
HC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFyLkS4OFQh|ryP NUHPTpA1W0GQR1XS
NB69 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TZdGlEPTB;MUCuOVA1OyEQvF2= NXzuU2ROW0GQR1XS
MFH-ino MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjyOmwyUUN3ME2xNE45OzB|IN88US=> MlLlV2FPT0WU
CCRF-CEM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\YTWM2OD1zMT61PVch|ryP NI\CO5FUSU6JRWK=
SK-N-DZ M17UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTVco83UUN3ME2xNk4xPDN4IN88US=> MnPJV2FPT0WU
NCI-H720 M3nTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\lTWM2OD1zMj6xO|A2KM7:TR?= Ml:wV2FPT0WU
HCC1187 NGjRc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHxR5U5UUN3ME2xNk4zODRzIN88US=> NUfNVYE2W0GQR1XS
IST-SL2 NV7lN4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf4[|RKSzVyPUGyMlQ5PzJizszN NV7RVItpW0GQR1XS
KE-37 NEL0flhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\Vb2lEPTB;MUKuO|k3PiEQvF2= NIrONVlUSU6JRWK=
HCC1599 M33hfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTvfnhKUUN3ME2xNk46ODZ7IN88US=> NY[1fnNUW0GQR1XS
A4-Fuk MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjufpVJUUN3ME2xNk46PTh4IN88US=> M1;jSHNCVkeHUh?=
NKM-1 M3nyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTaVolKSzVyPUGzMlI6OjVizszN M{HmUHNCVkeHUh?=
BE-13 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTj[YViUUN3ME2xN{44QTh7IN88US=> NXXoT3BOW0GQR1XS
MV-4-11 M2jhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7zTWM2OD1zND6wN|I1KM7:TR?= NH3hd4lUSU6JRWK=
OPM-2 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjpVJNKSzVyPUG0MlQxQDVizszN NGjrcmhUSU6JRWK=
KARPAS-422 NGLCdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\nSI5SUUN3ME2xOE42OTJ4IN88US=> NGDvVZdUSU6JRWK=
RPMI-8226 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW4NIN[UUN3ME2xOE45QTF3IN88US=> MkPwV2FPT0WU
KARPAS-45 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176OWlEPTB;MUWuO|cyPiEQvF2= NFv2[olUSU6JRWK=
SK-PN-DW Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\KbmxUUUN3ME2xOU45PjNzIN88US=> MonvV2FPT0WU
LC-2 M{jqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF4LkG1NFYh|ryP M3X0PHNCVkeHUh?=
NCI-H1648 NH74WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD1zNj6yOVQh|ryP Mo[2V2FPT0WU
RL95-2 NYnaW5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2SybWlEPTB;MU[uN|k4QCEQvF2= MkTGV2FPT0WU
KNS-42 NX:yRYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXzeWpyUUN3ME2xOk44Ojd2IN88US=> NIH1NJpUSU6JRWK=
RPMI-6666 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TPVmlEPTB;MU[uPVIyOSEQvF2= MXjTRW5ITVJ?
SIG-M5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5LkG5NFMh|ryP MV;TRW5ITVJ?
VA-ES-BJ NVftNYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i1dGlEPTB;MUeuO|Q2OSEQvF2= NX7ROopHW0GQR1XS
MONO-MAC-6 M{nwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;kTWM2OD1zNz65N|EzKM7:TR?= MlPGV2FPT0WU
LAN-6 M{D3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLnTWM2OD1zOD63OVU4KM7:TR?= MWHTRW5ITVJ?
A388 M3PiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF7LkOwOVkh|ryP NWrSWopxW0GQR1XS
SK-NEP-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\mcIJ{UUN3ME2yNE4zOTN{IN88US=> NXTFTpRiW0GQR1XS
TE-10 M4r4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJyLkWyNlEh|ryP MVPTRW5ITVJ?
HL-60 M4n5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jI[2lEPTB;MkCuPVA6QSEQvF2= MVjTRW5ITVJ?
MC116 NVX5dZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJzLkeyNlEh|ryP NFGzbXBUSU6JRWK=
SW962 NY\LNHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTPNmNKSzVyPUKxMlc6OTVizszN Mnr2V2FPT0WU
NOMO-1 M4L0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXZ[YJKSzVyPUKyMlY2PjRizszN MnLMV2FPT0WU
CTB-1 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XjN2lEPTB;MkKuPFY4OSEQvF2= NXPWNFJiW0GQR1XS
MRK-nu-1 NEDNWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zNW2lEPTB;MkKuPVA4PCEQvF2= M17oRXNCVkeHUh?=
GR-ST MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf3TWM2OD1{Mz63OkDPxE1? MUnTRW5ITVJ?
HH M2XWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHCTWM2OD1{ND6wNFMh|ryP MkfVV2FPT0WU
NCI-H1963 NFqzSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJ2LkC3PFIh|ryP MlPiV2FPT0WU
QIMR-WIL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTqTWM2OD1{ND64O|czKM7:TR?= MmGzV2FPT0WU
CGTH-W-1 M3PIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJ3LkC3NlMh|ryP NHvGS5FUSU6JRWK=
LP-1 NGHNdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfnfZZPUUN3ME2yOU43PTVzIN88US=> M4faU3NCVkeHUh?=
NCI-H748 NUe0TZRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLQ[YlKSzVyPUK2MlUyOzdizszN NUHOSGJCW0GQR1XS
PF-382 M2X2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq2dVN1UUN3ME2yO{4zOjJ|IN88US=> MoLMV2FPT0WU
ATN-1 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3QcnQ3UUN3ME2yO{4{PzN{IN88US=> MYnTRW5ITVJ?
L-540 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSzVZFUUUN3ME2yO{43PDV7IN88US=> NUDhbnNoW0GQR1XS
LXF-289 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33oZmlEPTB;MkeuO|UyQSEQvF2= NVzZRmVwW0GQR1XS
LS-513 NXfLXHNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ6LkG4NFch|ryP NWDQOo41W0GQR1XS
NCI-H1581 NUTHVIFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWwboFKSzVyPUOwMlM6PzZizszN MVjTRW5ITVJ?
ES6 M3rxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNyLk[4PVkh|ryP NFzrUYFUSU6JRWK=
SW982 NImzXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3hb|dKSzVyPUOwMlg2PjZizszN MlXVV2FPT0WU
DOHH-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTNzLkW4PVMh|ryP NV7zb3N7W0GQR1XS
DB NYHvRXZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPJb5VQUUN3ME2zN{46PDNzIN88US=> NE[2PW1USU6JRWK=
MPP-89 NVLzW5VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzFdnJ5UUN3ME2zOE4yPzV4IN88US=> MYXTRW5ITVJ?
LB831-BLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r2e2lEPTB;M{SuOVE5PCEQvF2= MkXjV2FPT0WU
NB5 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr6TWM2OD1|ND64OVM2KM7:TR?= NX;KSY05W0GQR1XS
GB-1 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fuOmlEPTB;M{WuNFQ3QSEQvF2= NETMWGFUSU6JRWK=
TE-15 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN3LkKyN|gh|ryP MWnTRW5ITVJ?
LC4-1 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3JZ4xmUUN3ME2zOU4{QDR5IN88US=> NVrVeYxKW0GQR1XS
NCI-H747 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;hTWM2OD1|Nj6xN|Y6KM7:TR?= NFSyb2FUSU6JRWK=
NTERA-S-cl-D1 NVn2U4JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLETWM2OD1|OD63N|Q4KM7:TR?= M1PGSHNCVkeHUh?=
SK-MM-2 M4\wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH31XpRKSzVyPUSwMlEyPDZizszN M2L5bnNCVkeHUh?=
TGW MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LDcWlEPTB;NEGuNFU3OyEQvF2= M13MS3NCVkeHUh?=
ONS-76 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TZbWlEPTB;NEKuOFg5OyEQvF2= NWWydpdCW0GQR1XS
CPC-N NGnRSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL5TWM2OD12Mj65PVcyKM7:TR?= NFHLNGJUSU6JRWK=
ES4 NY\XbnRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7DcoFrUUN3ME20OE41OTV|IN88US=> M2TrNHNCVkeHUh?=
Daudi MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GxZWlEPTB;NEWuNFgzPyEQvF2= NWPiWXZ1W0GQR1XS
MOLT-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXmTWM2OD12NT6wPFU{KM7:TR?= MUnTRW5ITVJ?
HT-144 NGrDN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DFU2lEPTB;NE[uO|I3KM7:TR?= NYnx[mNRW0GQR1XS
SW872 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDlcG1KSzVyPUS4MlE6OzNizszN NIHleIFUSU6JRWK=
D-283MED Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTR6LkO1OFIh|ryP MY\TRW5ITVJ?
NCI-H2126 NF;sS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnNN3BGUUN3ME20PE45PDd4IN88US=> NGrKVZBUSU6JRWK=
NCI-SNU-16 M{X0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfrOoVbUUN3ME20PU4zOTR|IN88US=> MljMV2FPT0WU
CESS NUPsb4JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3yTWM2OD12OT61NFg5KM7:TR?= MVLTRW5ITVJ?
A101D NV73eYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7XZXVKSzVyPUS5Mlk4OzZizszN MlTwV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03874273 Recruiting Inflammatory Myofibroblastic Tumor Federal Research Institute of Pediatric Hematology Oncology and Immunology February 1 2019 Phase 2|Phase 3
NCT03874273 Recruiting Inflammatory Myofibroblastic Tumor Federal Research Institute of Pediatric Hematology Oncology and Immunology February 1 2019 Phase 2|Phase 3
NCT03672643 Recruiting ALK-positive NSCLC Pfizer January 28 2019 Phase 4
NCT03672643 Recruiting ALK-positive NSCLC Pfizer January 28 2019 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products4

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID